Transcode Therapeutics Files 8-K on Financials
Ticker: RNAZ · Form: 8-K · Filed: Apr 5, 2024 · CIK: 1829635
Sentiment: neutral
Topics: financial-condition, operations-report
TL;DR
Transcode Therapeutics filed an 8-K on April 3rd detailing their financial condition.
AI Summary
Transcode Therapeutics, Inc. filed an 8-K on April 5, 2024, reporting on its results of operations and financial condition as of April 3, 2024. The filing indicates the company's principal executive offices are located at 6 Liberty Square, #2382, Boston, MA 02109, with a contact phone number of 857-301-6857.
Why It Matters
This 8-K filing provides an update on Transcode Therapeutics' operational and financial status, which is crucial for investors to assess the company's current health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting on financial condition and operations, not indicating any immediate significant risks or events.
Key Players & Entities
- Transcode Therapeutics, Inc. (company) — Registrant
- April 3, 2024 (date) — Date of earliest event reported
- April 5, 2024 (date) — Filing Date
- 6 Liberty Square, #2382, Boston, Massachusetts 02109 (address) — Principal executive offices
- 857-301-6857 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Transcode Therapeutics, Inc.?
The primary purpose is to report on the company's Results of Operations and Financial Condition as of April 3, 2024.
When was the earliest event reported in this filing?
The earliest event reported was on April 3, 2024.
What is the filing date of this 8-K report?
The filing date of this 8-K report is April 5, 2024.
Where are Transcode Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 6 Liberty Square, #2382, Boston, Massachusetts 02109.
What is the telephone number provided for Transcode Therapeutics, Inc.?
The telephone number provided is (857) 837-3099.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-04-05 16:51:01
Key Financial Figures
- $0.0001 — registered Common Stock, par value $0.0001 per share RNAZ The Nasdaq Capital M
Filing Documents
- tm2411028d1_8k.htm (8-K) — 28KB
- tm2411028d1_ex99-1.htm (EX-99.1) — 26KB
- 0001104659-24-044325.txt ( ) — 232KB
- rnaz-20240403.xsd (EX-101.SCH) — 3KB
- rnaz-20240403_lab.xml (EX-101.LAB) — 33KB
- rnaz-20240403_pre.xml (EX-101.PRE) — 22KB
- tm2411028d1_8k_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On April 3, 2024, TransCode Therapeutics, Inc. issued a press release announcing its financial results and other business highlights for the fourth quarter and full year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference. The information under this Item 2.02 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press release of TransCode Therapeutics, Inc. (concerning financial results) dated April 3, 2024, furnished hereto. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TransCode Therapeutics, Inc. Date: April 5, 2024 By: /s/ Thomas A. Fitzgerald Thomas A. Fitzgerald Interim Chief Executive Officer; Chief Financial Officer